Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorDouglas Adam Levinson
Estimating the term…
The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials.
An isolated nucleic acid which contains the following nucleotide sequence:
A method for diagnosing an immune disorder, comprising detecting in a patient sample, a gene transcript or gene product which is differentially expressed in a T helper cell subpopulation in an immune disorder state relative to in the T helper cell subpopulation in a non-immune disorder state.
A method for treating an immune disorder in a mammal, comprising administering to the mammal a compound that modulates a T helper cell subpopulation involved in causing the immune disorder so that symptoms of the immune disorder are ameliorated.
A method for treatment of an immune disorder comprising targeting a T helper cell subpopulation involved in the immune disorder so that the concentration of cells belonging to the T helper cell subpopulation is changed in a manner that ameliorates symptoms of the immune disorder.
A method for detecting an activated T helper cell subpopulation, comprising detecting a gene transcript or gene product which is expressed in the activated T helper cell subpopulation.
A method for monitoring the efficacy of a compound in clinical trials for the treatment of an immune disorder, comprising detecting, in a patient sample, a gene transcript or gene product which is differentially expressed in a T helper cell subpopulation in an immune disorder state relative to in the T helper cell subpopulation in a non-immune disorder state.
A method for modulating T helper cell responsiveness, comprising contacting a T helper cell with a compound so that the responsiveness of the T helper cell is modulated.
A method for detecting the state of T helper cell responsiveness, comprising detecting in a T helper cell a gene transcript or gene product which is differentially expressed in a T helper cell in a responsive state relative to a T helper cell in a nonresponsive state.
An isolated soluble 103 gene product comprising an Ig-tailed 103 gene product fusion protein.
An isolated soluble 200 gene product comprising an Ig-tailed 200 gene product fusion protein.
A method for identifying a compound that modulates the activity of a receptor target gene product, comprising:
The method of claim 73 wherein the seven transmembrane domain receptor target gene product is a 10 gene product.
The method of claim 73 wherein the cell is a Xenopus oocyte cell or a myeloma cell.
A 200 gene transgenic animal containing, integrated into its genome, a transgene capable of expressing a peptide or polypeptide comprising at least one 200 gene product domain as depicted in FIG. 17 or FIG. 24.
Dependencies are inferred from the claim text.